BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98. [PMID: 1658649 DOI: 10.1056/NEJM199111213252107] [Cited by in Crossref: 745] [Cited by in F6Publishing: 776] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Grazzini S, Rizzo C, Conticini E, D'Alessandro R, La Barbera L, D'Alessandro M, Falsetti P, Bargagli E, Guggino G, Cantarini L, Frediani B. The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review. Autoimmun Rev 2023;22:103264. [PMID: 36549353 DOI: 10.1016/j.autrev.2022.103264] [Reference Citation Analysis]
2 Cochrane Neuromuscular Group, Joost Raaphorst, Nicola J Gullick, Nicolo Pipitone, Farhad Shokraneh, Ruth Brassington, Saadia Sasha Ali, Patrick A Gordon. Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies. Cochrane Database Syst Rev 2023;2023:CD014510. [ DOI: 10.1002/14651858.CD014510] [Reference Citation Analysis]
3 Kara M, Kara MM, Diniz G. Inflammatory Myositis Without Borders, Case Report.. [DOI: 10.21203/rs.3.rs-2493115/v1] [Reference Citation Analysis]
4 Sener S, Batu ED, Sari S, Cuceoglu MK, Yildiz AE, Talim B, Aydingoz U, Ozen S, Haliloglu G. A Child with Refractory and Relapsing Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy: Case-Based Review. J Neuromuscul Dis 2023. [PMID: 36617789 DOI: 10.3233/JND-221557] [Reference Citation Analysis]
5 Oh SJ, King PH, Schindler A. Life-Long Steroid Responsive Familial Myopathy With Docking Protein 7 Mutation. Journal of Clinical Neuromuscular Disease 2022;24:80-84. [DOI: 10.1097/cnd.0000000000000398] [Reference Citation Analysis]
6 Yin B, Xiao J, Wang X, Li X, Guan Y, Chen J, Han P, Li K, Wang J. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature. Front Med 2022;9. [DOI: 10.3389/fmed.2022.950801] [Reference Citation Analysis]
7 Jia Q, Hao R, Lu X, Sun S, Shao J, Su X, Huang Q. Identification of hub biomarkers and immune cell infiltration characteristics of polymyositis by bioinformatics analysis. Front Immunol 2022;13:1002500. [DOI: 10.3389/fimmu.2022.1002500] [Reference Citation Analysis]
8 Murakami A, Noda S, Kazuta T, Hirano S, Kimura S, Nakanishi H, Matsuo K, Tsujikawa K, Iida M, Koike H, Sakamoto K, Hara Y, Kuru S, Kadomatsu K, Shimamura T, Ogi T, Katsuno M. Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis. Ann Clin Transl Neurol. [DOI: 10.1002/acn3.51657] [Reference Citation Analysis]
9 Kuroda H, Yamaguchi A, Sugata S, Hamada T, Moriuchi R, Wada K, Tamaru Y, Kusunoki R, Kuwai T, Kouno H, Kurashige T, Torii T, Saito A, Kuraoka K, Kohno H. Advanced gallbladder cancer accompanied with cancer-associated dermatomyositis: A case report and literature review. Medicine (Baltimore) 2022;101:e29477. [PMID: 35801780 DOI: 10.1097/MD.0000000000029477] [Reference Citation Analysis]
10 Fan W, Li Z, Wang Y, Zhang C, Liu H, Wang D, Bai Y, Luo S, Li Y, Qin Q, Chen W, Yong L, Zhen Q, Yu Y, Ge H, Mao Y, Cao L, Zhang R, Hu X, Yu Y, Li B, Sun L. Imputation of the major histocompatibility complex region identifies major independent variants associated with bullous pemphigoid and dermatomyositis in Han Chinese. J Dermatol 2022. [PMID: 35751838 DOI: 10.1111/1346-8138.16499] [Reference Citation Analysis]
11 Wang CR, Tsai HW. Autoimmune liver diseases in systemic rheumatic diseases. World J Gastroenterol 2022; 28(23): 2527-2545 [DOI: 10.3748/wjg.v28.i23.2527] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Ruscitti P, Di Cola I, Di Muzio C, Italiano N, Ursini F, Giacomelli R, Cipriani P. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Autoimmun Rev 2022;:103114. [PMID: 35595050 DOI: 10.1016/j.autrev.2022.103114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Dalakas MC. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol 2022;:1-11. [PMID: 35323101 DOI: 10.1080/1744666X.2022.2054803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Bonroy C, Piette Y, Allenbach Y, Bossuyt X, Damoiseaux J. Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up. Journal of Translational Autoimmunity 2022. [DOI: 10.1016/j.jtauto.2022.100148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Pilania K, Jankharia B. Role of MRI in idiopathic inflammatory myopathies: a review article. Acta Radiol 2022;63:200-13. [PMID: 33554607 DOI: 10.1177/0284185121990305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wu Y, Zhao Z, Zhang J, Wang Y, Song X. Identification of Hub Genes and Biological Pathways in Inclusion Body Myositis Using Bioinformatics Analysis. IJGM 2022;Volume 15:1281-93. [DOI: 10.2147/ijgm.s346965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Salazar-villa G, Rodríguez-prada C, Bonfante-tamara M, Restrepo-correa R, Rodríguez-padilla LM, Mesa-navas MA, Velásquez-franco CJ. Clinical characterization of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey. Revista Colombiana de Reumatología (English Edition) 2022;29:9-18. [DOI: 10.1016/j.rcreue.2020.09.005] [Reference Citation Analysis]
18 Desjardins A. Diagnosis and treatment of paraneoplastic neurological disorders. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00029-3] [Reference Citation Analysis]
19 Jabbouri S, Halperin SJ, Pathak N, Wilhelm CV, Ng M, Arsoy D. Knee Arthrodesis for Mycobacterium avium Complex Native-Knee Septic Arthritis in a Patient with Dermatomyositis. JBJS Case Connector 2022;12. [DOI: 10.2106/jbjs.cc.22.00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Salazar-villa G, Rodríguez-prada C, Bonfante-tamara M, Restrepo-correa R, Rodríguez-padilla LM, Mesa-navas MA, Velásquez-franco CJ. Caracterización clínica de pacientes con miopatía inflamatoria en 2 instituciones de alta complejidad en Colombia: estudio descriptivo. Revista Colombiana de Reumatología 2022;29:9-18. [DOI: 10.1016/j.rcreu.2020.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dalakas MC. Treatment and Management of Autoimmune Myopathies. Neuromuscular Disorders 2022. [DOI: 10.1016/b978-0-323-71317-7.00022-6] [Reference Citation Analysis]
22 Xiao YS, Zhu FY, Luo L, Xing XY, Li YH, Zhang XW, Shen DH. [Clinical and immunological characteristics of 88 cases of overlap myositis]. Beijing Da Xue Xue Bao Yi Xue Ban 2021;53:1088-93. [PMID: 34916687] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Ochala J, Finno CJ, Valberg SJ. Myofibre Hyper-Contractility in Horses Expressing the Myosin Heavy Chain Myopathy Mutation, MYH1E321G. Cells 2021;10:3428. [PMID: 34943936 DOI: 10.3390/cells10123428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Labeit B, Grond T, Beule AG, Boehmer M, Thomas C, Muhle P, Claus I, Roderigo M, Rudack C, Wiendl H, Dziewas R, Warnecke T, Suntrup-Krueger S. Detecting myositis as a cause of unexplained dysphagia: Proposal for a diagnostic algorithm. Eur J Neurol 2021. [PMID: 34862828 DOI: 10.1111/ene.15202] [Reference Citation Analysis]
25 Chanbour H, Jiblawi A, Aboudalle A, Alalman O, Chahine Elsett Z. Association of Silicosis and Dermatomyositis: Case Report and Literature Review. Cureus 2021. [DOI: 10.7759/cureus.19875] [Reference Citation Analysis]
26 Tsamis KI, Boutsoras C, Kaltsonoudis E, Pelechas E, Nikas IP, Simos YV, Voulgari PV, Sarmas I. Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Crit Rev Clin Lab Sci 2021;:1-22. [PMID: 34767470 DOI: 10.1080/10408363.2021.2000584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Borges NH, Godoy TM, Kahlow BS. Onset of dermatomyositis in close association with COVID-19-a first case reported. Rheumatology (Oxford) 2021;60:SI96. [PMID: 33757122 DOI: 10.1093/rheumatology/keab290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
28 Pasoglou V, Van Nieuwenhove S, Peeters F, Duchêne G, Kirchgesner T, Lecouvet FE. 3D Whole-Body MRI of the Musculoskeletal System. Semin Musculoskelet Radiol 2021;25:441-54. [PMID: 34547810 DOI: 10.1055/s-0041-1730401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Stathopoulos P, Dalakas MC. Autoimmune Neurogenic Dysphagia. Dysphagia 2021. [PMID: 34226958 DOI: 10.1007/s00455-021-10338-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Pfister PB, Knols RH, de Bie RA, de Bruin ED. Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies. Arch Physiother 2021;11:14. [PMID: 34039438 DOI: 10.1186/s40945-021-00108-z] [Reference Citation Analysis]
31 Nagawa K, Suzuki M, Yamamoto Y, Inoue K, Kozawa E, Mimura T, Nakamura K, Nagata M, Niitsu M. Texture analysis of muscle MRI: machine learning-based classifications in idiopathic inflammatory myopathies. Sci Rep 2021;11:9821. [PMID: 33972636 DOI: 10.1038/s41598-021-89311-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
32 Hajkhan AM, Pérez AA, Heras CB, Gómez AP. Miopatías inflamatorias idiopáticas. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1799-1808. [DOI: 10.1016/j.med.2021.04.010] [Reference Citation Analysis]
33 Nissan E, Watad A, Cohen AD, Sharif K, Nissan J, Amital H, Shovman O, Bragazzi NL. Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study. Int J Environ Res Public Health 2021;18:3983. [PMID: 33920065 DOI: 10.3390/ijerph18083983] [Reference Citation Analysis]
34 Hankiewicz K. Évolution des critères diagnostiques des myopathies inflammatoires. Pratique Neurologique - FMC 2021;12:64-68. [DOI: 10.1016/j.praneu.2021.02.002] [Reference Citation Analysis]
35 Findlay AR, Bucelli RC. Immune and Inflammatory Myopathies. Neuroimmunology 2021. [DOI: 10.1007/978-3-030-61883-4_20] [Reference Citation Analysis]
36 Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol 2020;39:289-301. [PMID: 33458584 DOI: 10.36185/2532-1900-032] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
37 Fer F, Allenbach Y, Benveniste O. [Myositis: From classification to diagnosis]. Rev Med Interne 2021;42:392-400. [PMID: 33248855 DOI: 10.1016/j.revmed.2020.10.379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Corrado B, Ciardi G, Lucignano L. Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature. Neurol Int 2020;12:77-88. [PMID: 33255200 DOI: 10.3390/neurolint12030015] [Reference Citation Analysis]
39 Arai-Okuda H, Norikane T, Yamamoto Y, Mitamura K, Fujimoto K, Takami Y, Wakiya R, Nakashima S, Dobashi H, Nishiyama Y. 18F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes. Eur J Hybrid Imaging 2020;4:14. [PMID: 34191182 DOI: 10.1186/s41824-020-00084-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Mageriu V, Manole E, Bastian AE, Staniceanu F. Role of Myokines in Myositis Pathogenesis and Their Potential to be New Therapeutic Targets in Idiopathic Inflammatory Myopathies. J Immunol Res 2020;2020:9079083. [PMID: 32775472 DOI: 10.1155/2020/9079083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
41 Xu Q, Li QX, Bi FF, Duan HQ, Luo YB, Yang H. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies. Clin Rheumatol 2021;40:613-24. [PMID: 32671659 DOI: 10.1007/s10067-020-05274-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
42 Nakanishi Y, Yamaguchi K, Yoshida Y, Sakamoto S, Horimasu Y, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Hirata S, Fujitaka K, Hamada H, Sugiyama E, Hattori N. Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis. Intern Med 2020;59:2553-8. [PMID: 32581161 DOI: 10.2169/internalmedicine.4702-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Qazi A, Malik F, Shafi L, Basar S, Qazi A. Young-onset Amyotrophic Lateral Sclerosis with Rare Skin Manifestation: Case Report and Literature Review. Cureus 2020;12:e7844. [PMID: 32483495 DOI: 10.7759/cureus.7844] [Reference Citation Analysis]
44 Zhou L, Shin SC, Cai C. A 45-Year-Old Woman with Proximal Limb Weakness and Skin Peeling on Fingertips. A Case-Based Guide to Neuromuscular Pathology 2020. [DOI: 10.1007/978-3-030-25682-1_5] [Reference Citation Analysis]
45 Muskelerkrankungen. Diagnostik und Therapie neurologischer Erkrankungen 2020. [DOI: 10.1016/b978-3-437-21882-8.00006-2] [Reference Citation Analysis]
46 Álvarez-machancoses Ó, deAndrés-Galiana E, Fernández-martínez JL, Kloczkowski A. The Utilization of Different Classifiers to Perform Drug Repositioning in Inclusion Body Myositis Supports the Concept of Biological Invariance. Artificial Intelligence and Soft Computing 2020. [DOI: 10.1007/978-3-030-61401-0_55] [Reference Citation Analysis]
47 Mehta TR, Bhatia K, Arora N. Rapidly Progressive Muscle Weakness. Neuromuscular Urgencies and Emergencies 2020. [DOI: 10.1007/978-3-030-53145-4_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Santos AMD, Oliveira DSD, Misse RG, Souza JMD, Shinjo SK. Exercício físico nas miopatias autoimunes sistêmicas: novas evidências para um antigo aliado. Rev Paul Reumatol 2019. [DOI: 10.46833/reumatologiasp.2019.18.4.25-30] [Reference Citation Analysis]
49 Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis - challenges in diagnosis and management. J Transl Autoimmun 2019;2:100018. [PMID: 32743506 DOI: 10.1016/j.jtauto.2019.100018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
50 Yongchairat K, Tanboon J, Waisayarat J, Narongroeknawin P, Chevaisrakul P, Dejthevaporn C, Katchamart W. Clinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control study. Clin Rheumatol 2019;38:3459-69. [PMID: 31446540 DOI: 10.1007/s10067-019-04756-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
51 Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm 2019;6:e581. [PMID: 31355317 DOI: 10.1212/NXI.0000000000000581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
52 Baschung Pfister P, de Bruin ED, Bastiaenen CHG, Maurer B, Knols RH. Reliability and validity of the German version of the Myositis Activities Profile (MAP) in patients with inflammatory myopathy. PLoS One 2019;14:e0217173. [PMID: 31158240 DOI: 10.1371/journal.pone.0217173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
53 Van Thillo A, Vulsteke JB, Van Assche D, Verschueren P, De Langhe E. Physical therapy in adult inflammatory myopathy patients: a systematic review. Clin Rheumatol 2019;38:2039-51. [PMID: 31115788 DOI: 10.1007/s10067-019-04571-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
54 Zhang T, Xu J, Liu Y, Liu J. Metabolomic profiling for identification of potential biomarkers in patients with dermatomyositis. Metabolomics 2019;15:77. [PMID: 31087209 DOI: 10.1007/s11306-019-1539-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
55 Roos A, Preusse C, Hathazi D, Goebel HH, Stenzel W. Proteomic Profiling Unravels a Key Role of Specific Macrophage Subtypes in Sporadic Inclusion Body Myositis. Front Immunol 2019;10:1040. [PMID: 31143183 DOI: 10.3389/fimmu.2019.01040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
56 Ukichi T, Yoshida K, Matsushima S, Kawakami G, Noda K, Furuya K, Kurosaka D. MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis. RMD Open 2019;5:e000850. [PMID: 30997152 DOI: 10.1136/rmdopen-2018-000850] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
57 Santos LR, Isenberg D. Myositis. Contemporary Clinical Neuroscience 2019. [DOI: 10.1007/978-3-030-19515-1_27] [Reference Citation Analysis]
58 Heath KR, Fazel N. Oral Signs of Connective Tissue Disease. Oral Signs of Systemic Disease 2019. [DOI: 10.1007/978-3-030-10863-2_6] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Yoo IS, Kim J. The Role of Autoantibodies in Idiopathic Inflammatory Myopathies. J Rheum Dis 2019;26:165. [DOI: 10.4078/jrd.2019.26.3.165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Koo B. Perioperative Anesthetic Management of a Patient with Dermatomyositis. Soonchunhyang Med Sci 2018;24:232-235. [DOI: 10.15746/sms.18.046] [Reference Citation Analysis]
61 Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurology & Clinical Neurosc 2019;7:3-21. [DOI: 10.1111/ncn3.12223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
62 Georgiev T, Stoilov R. Bulgarian rheumatology: science and practice in a cost-constrained environment. Rheumatol Int 2019;39:417-29. [PMID: 30413925 DOI: 10.1007/s00296-018-4202-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
63 Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864. [PMID: 30245744 DOI: 10.1177/1756286418799864] [Cited by in Crossref: 106] [Cited by in F6Publishing: 113] [Article Influence: 21.2] [Reference Citation Analysis]
64 Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, Adams S, Marasco E, Rosser EC, Radziszewska A, Carsetti R, Ioannou Y, Beales PL, Kelberman D, Isenberg DA, Mauri C, Nistala K, Wedderburn LR. CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. Front Immunol 2018;9:1372. [PMID: 29988398 DOI: 10.3389/fimmu.2018.01372] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
65 Sun L, Dong Y, Zhang N, Lv X, Chen Q, Wei W. [18F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis. Exp Ther Med 2018;15:5023-8. [PMID: 29805526 DOI: 10.3892/etm.2018.6066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
66 Benveniste O. Miosite da corpi inclusi. EMC - Neurologia 2018;18:1-7. [DOI: 10.1016/s1634-7072(18)89405-3] [Reference Citation Analysis]
67 Baschung Pfister P, de Bruin ED, Sterkele I, Maurer B, de Bie RA, Knols RH. Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: An intra- and interrater reliability and validity study. PLoS One 2018;13:e0194531. [PMID: 29596450 DOI: 10.1371/journal.pone.0194531] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
68 Leclair V, Lundberg IE. New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter. Curr Rheumatol Rep 2018;20:18. [PMID: 29550929 DOI: 10.1007/s11926-018-0726-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
69 Finno CJ, Gianino G, Perumbakkam S, Williams ZJ, Bordbari MH, Gardner KL, Burns E, Peng S, Durward-Akhurst SA, Valberg SJ. A missense mutation in MYH1 is associated with susceptibility to immune-mediated myositis in Quarter Horses. Skelet Muscle 2018;8:7. [PMID: 29510741 DOI: 10.1186/s13395-018-0155-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
70 Herbelet S, De Vlieghere E, Gonçalves A, De Paepe B, Schmidt K, Nys E, Weynants L, Weis J, Van Peer G, Vandesompele J, Schmidt J, De Wever O, De Bleecker JL. Localization and Expression of Nuclear Factor of Activated T-Cells 5 in Myoblasts Exposed to Pro-inflammatory Cytokines or Hyperosmolar Stress and in Biopsies from Myositis Patients. Front Physiol 2018;9:126. [PMID: 29515464 DOI: 10.3389/fphys.2018.00126] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
71 Stenzel W. Physiopathologie des différentes myopathies inflammatoires. Bulletin de l'Académie Nationale de Médecine 2018;202:79-89. [DOI: 10.1016/s0001-4079(19)30342-5] [Reference Citation Analysis]
72 Finol HJ, Osorio-vega HL, Dorta-ledezma R, Roschman-gonzález A, Muller B, de Oca IM. Ultrastructural Aspects of Apoptosis in Systemic Sclerosis Inflammatory Myopathy. MR 2018;06:1-7. [DOI: 10.4236/mr.2018.61001] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Benveniste O. La myosite à inclusions. Bulletin de l'Académie Nationale de Médecine 2018;202:91-103. [DOI: 10.1016/s0001-4079(19)30343-7] [Reference Citation Analysis]
74 Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) . EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 2017;3:e000507. [PMID: 29177080 DOI: 10.1136/rmdopen-2017-000507] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 13.2] [Reference Citation Analysis]
75 Chen S, Wen X, Li L, Li J, Li Y, Wang Q, Yuan H, Zhang F, Li Y. Single nucleotide polymorphisms in the ETS1 gene are associated with idiopathic inflammatory myopathies in a northern Chinese Han population. Sci Rep 2017;7:13128. [PMID: 29030598 DOI: 10.1038/s41598-017-13385-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Nayak R. Practical approach to the patient with acute neuromuscular weakness. World J Clin Cases 2017; 5(7): 270-279 [PMID: 28798922 DOI: 10.12998/wjcc.v5.i7.270] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
77 Di Piazza A, Vernuccio F, Costanzo M, Scopelliti L, Picone D, Midiri F, Salvaggi F, Cupido F, Galia M, Salerno S, Lo Casto A, Midiri M, Lo Re G, Lagalla R. The Videofluorographic Swallowing Study in Rheumatologic Diseases: A Comprehensive Review. Gastroenterol Res Pract 2017;2017:7659273. [PMID: 28706536 DOI: 10.1155/2017/7659273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Kidambi TD, Schmajuk G, Gross AJ, Ostroff JW, Terdiman JP, Lee JK. Endoscopy is of low yield in the identification of gastrointestinal neoplasia in patients with dermatomyositis: A cross-sectional study. World J Gastroenterol 2017; 23(26): 4788-4795 [PMID: 28765700 DOI: 10.3748/wjg.v23.i26.4788] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Chen J, Wang J, Zhang J, Pu C. 3-n-Butylphthalide reduces the oxidative damage of muscles in an experimental autoimmune myositis animal model. Exp Ther Med 2017;14:2085-93. [PMID: 28962128 DOI: 10.3892/etm.2017.4766] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
80 Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 2016;280:39-51. [PMID: 27320359 DOI: 10.1111/joim.12524] [Cited by in Crossref: 104] [Cited by in F6Publishing: 109] [Article Influence: 17.3] [Reference Citation Analysis]
81 Keller CW, Schmidt J, Lünemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol 2017;4:422-45. [PMID: 28589170 DOI: 10.1002/acn3.419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
82 Cox JT, Gullotti DM, Mecoli CA, Lahouti AH, Albayda J, Paik J, Johnson C, Danoff SK, Mammen AL, Christopher-Stine L. "Hiker's feet": a novel cutaneous finding in the inflammatory myopathies. Clin Rheumatol 2017;36:1683-6. [PMID: 28389987 DOI: 10.1007/s10067-017-3598-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
83 Selva O’callaghan A, Trallero Araguás E, Labrador Horrillo M, Grau Junyent J. Miopatías inflamatorias. Medicine - Programa de Formación Médica Continuada Acreditado 2017;12:1679-1689. [DOI: 10.1016/j.med.2017.03.001] [Reference Citation Analysis]
84 Santacatterina F, Sánchez-Aragó M, Catalán-García M, Garrabou G, de Arenas CN, Grau JM, Cardellach F, Cuezva JM. Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis. J Transl Med 2017;15:29. [PMID: 28183315 DOI: 10.1186/s12967-017-1136-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
85 Cavazzana I, Fredi M, Selmi C, Tincani A, Franceschini F. The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clin Rev Allergy Immunol 2017;52:88-98. [PMID: 26514357 DOI: 10.1007/s12016-015-8517-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
86 Mannering IK, Yu Y, Grando SA. Intravenous Immunoglobulin: Dermatologic Uses and Mechanisms of Action. Clinical and Basic Immunodermatology 2017. [DOI: 10.1007/978-3-319-29785-9_50] [Reference Citation Analysis]
87 우혜원, 김수연, 최선아, 채종희, 임병찬, 황희, 최지은, 김기중, 조재소, 김헌민. Clinical Characteristics and Treatment Response of Juvenile Dermatomyositis. journalofthekoreanchildneurologysociety 2016;24:232-239. [DOI: 10.26815/jkcns.2016.24.4.232] [Reference Citation Analysis]
88 Wang Q, Chen S, Li Y, Li P, Wu C, Wu Z, Wu Q, Sun F, Li J, Zheng W, Deng C, Zhang F, Li Y. Positive association of genetic variations in the phospholipase C-like 1 gene with dermatomyositis in Chinese Han. Immunol Res 2016;64:204-12. [PMID: 26603167 DOI: 10.1007/s12026-015-8738-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
89 Kubeček O, Soukup T, Paulík A, Kopecký J. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. BMC Cancer 2016;16:684. [PMID: 27561848 DOI: 10.1186/s12885-016-2715-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
90 Shu X, Peng Q, Lu X, Wang G. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. PLoS One 2016;11:e0161436. [PMID: 27537498 DOI: 10.1371/journal.pone.0161436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
91 Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol 2016;7:64. [PMID: 27242652 DOI: 10.3389/fneur.2016.00064] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
92 Jain T, Basher R, Bhattacharya A, Mittal B, Shukla J, Prakash M. 18 F-FDG PET/CT in diagnosis and response evaluation in an unusual case of antisynthetase syndrome presenting as pyrexia of unknown origin. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2016;35:197-199. [DOI: 10.1016/j.remnie.2015.08.003] [Reference Citation Analysis]
93 Jain T, Basher R, Bhattacharya A, Mittal B, Shukla J, Prakash M. 18F-FDG PET/CT in diagnosis and response evaluation in an unusual case of antisynthetase syndrome presenting as pyrexia of unknown origin. Revista Española de Medicina Nuclear e Imagen Molecular 2016;35:197-199. [DOI: 10.1016/j.remn.2015.08.013] [Reference Citation Analysis]
94 Zhang X, Wang Y, Ma G, Zhang L, Jing H, DU J. Dermatomyositis as a symptom of primary lung cancer: A case report and review of the literature. Oncol Lett 2016;11:3413-6. [PMID: 27123126 DOI: 10.3892/ol.2016.4418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
95 Dalakas MC. Polymyositis. International Neurology 2016. [DOI: 10.1002/9781118777329.ch120] [Reference Citation Analysis]
96 Dalakas MC. Dermatomyositis. International Neurology 2016. [DOI: 10.1002/9781118777329.ch121] [Reference Citation Analysis]
97 Leverenz D, Zaha O, Crofford LJ, Chung CP. Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology. Clin Rheumatol 2016;35:1541-7. [PMID: 27041384 DOI: 10.1007/s10067-016-3242-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
98 Yoshifuji H. Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies. Clin Med Insights Circ Respir Pulm Med 2015;9:141-6. [PMID: 27081322 DOI: 10.4137/CCRPM.S36748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
99 Chen S, Wu W, Li J, Wang Q, Li Y, Wu Z, Zheng W, Wu Q, Wu C, Zhang F, Li Y. Single nucleotide polymorphisms in the FAM167A-BLK gene are associated with polymyositis/dermatomyositis in the Han Chinese population. Immunol Res 2015;62:153-62. [PMID: 25846585 DOI: 10.1007/s12026-015-8646-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
100 Dalakas MC. The Spectrum of Inflammatory Myopathies: Dermatomyositis, Polymyositis, Necrotizing Myositis, and Inclusion-Body Myositis. Acquired Neuromuscular Disorders 2016. [DOI: 10.1007/978-3-319-29514-5_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Filosto M, Pichiecchio A, Padovani A, Gasparotti R. Imaging of the Muscle. Acquired Neuromuscular Disorders 2016. [DOI: 10.1007/978-3-319-29514-5_3] [Reference Citation Analysis]
102 Lehman HK, Ballow M. Immunoglobulin Therapy. Pediatric Allergy: Principles and Practice 2016. [DOI: 10.1016/b978-0-323-29875-9.00015-x] [Reference Citation Analysis]
103 Albrecht I, Wick C, Hallgren Å, Tjärnlund A, Nagaraju K, Andrade F, Thompson K, Coley W, Phadke A, Diaz-Gallo LM, Bottai M, Nennesmo I, Chemin K, Herrath J, Johansson K, Wikberg A, Ytterberg AJ, Zubarev RA, Danielsson O, Krystufkova O, Vencovsky J, Landegren N, Wahren-Herlenius M, Padyukov L, Kämpe O, Lundberg IE. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest 2015;125:4612-24. [PMID: 26551678 DOI: 10.1172/JCI81031] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
104 Mateus S, Malheiro M, Santos MP, Costa R. Dermatomyositis onset in the puerperium period. BMJ Case Rep 2015;2015:bcr2015211025. [PMID: 26361805 DOI: 10.1136/bcr-2015-211025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
105 Baschung Pfister P, de Bruin ED, Tobler-Ammann BC, Maurer B, Knols RH. The relevance of applying exercise training principles when designing therapeutic interventions for patients with inflammatory myopathies: a systematic review. Rheumatol Int 2015;35:1641-54. [PMID: 26271469 DOI: 10.1007/s00296-015-3343-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
106 Bien CG, Bien C. Therapeutisches Management von Autoimmun-Enzephalitiden. Z Epileptol 2015;28:201-206. [DOI: 10.1007/s10309-015-0006-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
107 Harris-Love MO, Joe G, Davenport TE, Koziol D, Abbett Rose K, Shrader JA, Vasconcelos OM, McElroy B, Dalakas MC. Reliability of the adult myopathy assessment tool in individuals with myositis. Arthritis Care Res (Hoboken) 2015;67:563-70. [PMID: 25201624 DOI: 10.1002/acr.22473] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
108 Karri SB, Kannan MA, Rajashekhar L, Uppin MS, Challa S. Clinico pathological study of adult dermatomyositis: Importance of muscle histology in the diagnosis. Ann Indian Acad Neurol. 2015;18:194-199. [PMID: 26019418 DOI: 10.4103/0972-2327.150603] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
109 Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BG. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 2015;129:611-24. [PMID: 25579751 DOI: 10.1007/s00401-015-1384-5] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 10.0] [Reference Citation Analysis]
110 Prayson RA. Muscle and peripheral nerve pathology. Silverberg's Principles and Practice of Surgical Pathology and Cytopathology 2015. [DOI: 10.1017/9781139137201.046] [Reference Citation Analysis]
111 Rosenbohm A, Buckert D, Gerischer N, Walcher T, Kassubek J, Rottbauer W, Ludolph AC, Bernhardt P. Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. J Neurol 2015;262:949-56. [PMID: 25673126 DOI: 10.1007/s00415-014-7623-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
112 Allenbach Y, Benveniste O. Polimiositis, dermatomiositis y otras miopatías inflamatorias idiopáticas. EMC - Aparato Locomotor 2015;48:1-11. [DOI: 10.1016/s1286-935x(15)70083-3] [Reference Citation Analysis]
113 van de Vlekkert J, Hoogendijk JE, de Visser M. Long-term follow-up of 62 patients with myositis. J Neurol 2014;261:992-8. [PMID: 24658663 DOI: 10.1007/s00415-014-7313-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
114 Lundberg IE. Inflammatory muscle disease: etiology and pathogenesis. Rheumatology 2015. [DOI: 10.1016/b978-0-323-09138-1.00149-2] [Reference Citation Analysis]
115 Nouh A, Carbunar O, Ruland S. Neurology of rheumatologic disorders. Curr Neurol Neurosci Rep 2014;14:456. [PMID: 24871965 DOI: 10.1007/s11910-014-0456-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
116 Zhang L, Fu XH, Yu Y, Shui RH, Li C, Zeng HY, Qiao YL, Ni LY, Wang Q. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis. Lab Invest 2015;95:65-77. [PMID: 25384123 DOI: 10.1038/labinvest.2014.135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
117 Selva-O'Callaghan A, Ramos Casals M, Grau Junyent JM. [Biologic therapy in idiopathic inflammatory myopathy]. Med Clin (Barc) 2014;143:275-80. [PMID: 24393419 DOI: 10.1016/j.medcli.2013.11.009] [Reference Citation Analysis]
118 Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014;83:426-33. [PMID: 24975859 DOI: 10.1212/WNL.0000000000000642] [Cited by in Crossref: 139] [Cited by in F6Publishing: 141] [Article Influence: 15.4] [Reference Citation Analysis]
119 Crescioli C. Vitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathy. Biomed Res Int 2014;2014:949730. [PMID: 24895631 DOI: 10.1155/2014/949730] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
120 Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol 2014;34 Suppl 1:S120-6. [PMID: 24722854 DOI: 10.1007/s10875-014-0024-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
121 Gupta S, Kim SM, Wang Y, Dinasarapu AR, Subramaniam S. Statistical insights into major human muscular diseases. Hum Mol Genet 2014;23:3772-8. [PMID: 24569163 DOI: 10.1093/hmg/ddu090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
122 Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C. P62/SQSTM1 at the interface of aging, autophagy, and disease. Age (Dordr) 2014;36:9626. [PMID: 24557832 DOI: 10.1007/s11357-014-9626-3] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 10.0] [Reference Citation Analysis]
123 Peng QL, Shu XM, Tian XL, Lu X, Wang GC. Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis. Arthritis Res Ther 2014;16:R26. [PMID: 24467773 DOI: 10.1186/ar4454] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
124 Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014;13:367-71. [PMID: 24424190 DOI: 10.1016/j.autrev.2014.01.022] [Cited by in Crossref: 177] [Cited by in F6Publishing: 193] [Article Influence: 19.7] [Reference Citation Analysis]
125 Goyal N, Chad DA. Inflammatory Myopathies. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_65] [Reference Citation Analysis]
126 Boonyapisit K. Infectious and Granulomatous Myopathies. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_69] [Reference Citation Analysis]
127 An SH, Na HY, Kang SH, Park SY, Yu HM, Lee CH, Kim JW, Kwon SW, Lee J, Kim H, Lee S. Muscle Weakness in a Patient with History of Poliomyelitis: A Differential Diagnosis for Post-polio Syndrome (PPS) and Dermatomyositis. J Rheum Dis 2014;21:147. [DOI: 10.4078/jrd.2014.21.3.147] [Reference Citation Analysis]
128 Mitchell JA, Waclawik AJ. Muscle Biopsy in Diagnosis of Neuromuscular Disorders: The Technical Aspects, Clinical Utility, and Recent Advances. Journal of Histotechnology 2013;30:257-69. [DOI: 10.1179/his.2007.30.4.257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
129 Castro A, Barroso A, Parente B. Dermatomyositis as the first manifestation of a lung tumor. Revista Portuguesa de Pneumologia (English Edition) 2013;19:179-183. [DOI: 10.1016/j.rppnen.2013.02.004] [Reference Citation Analysis]
130 Lavin JM, Tieu D, Maddalozzo J. Complementary and integrative treatments: swallowing disorders. Otolaryngol Clin North Am 2013;46:447-60. [PMID: 23764821 DOI: 10.1016/j.otc.2013.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
131 Stuhlmüller B, Feist E, Häupl T, Burmester GR, Pipitone N. [New aspects on the pathogenesis of myositis]. Z Rheumatol 2013;72:209-19. [PMID: 23515563 DOI: 10.1007/s00393-012-1078-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Gundogdu BM, Cilingiroglu M. Chronic inflammatory muscle diseases and risk of coronary artery disease. Curr Atheroscler Rep 2013;15:308. [PMID: 23341225 DOI: 10.1007/s11883-012-0308-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
133 Malviya G, Anzola KL, Podestà E, Laganà B, Del Mastro C, Dierckx RA, Scopinaro F, Signore A. (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol Imaging Biol. 2012;14:637-646. [PMID: 22127469 DOI: 10.1007/s11307-011-0527-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
134 Briemberg HR. Myopathies due to Systemic Disease. Neurological Disorders due to Systemic Disease 2013. [DOI: 10.1002/9781118414019.ch13] [Reference Citation Analysis]
135 Guinee DG, Travis WD. The lungs in connective tissue disease. Spencer's Pathology of the Lung 2013. [DOI: 10.1017/cbo9781139018760.024] [Reference Citation Analysis]
136 Kim JJ, Lee SH, Paik SS, Yoo DH. The Utility of Magnetic Resonance Imaging in Inflammatory Myopathy. J Rheum Dis 2013;20:297. [DOI: 10.4078/jrd.2013.20.5.297] [Reference Citation Analysis]
137 Nagaraju K, Lundberg IE. Inflammatory Diseases of Muscle and Other Myopathies. Kelley's Textbook of Rheumatology 2013. [DOI: 10.1016/b978-1-4377-1738-9.00085-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Preston DC, Shapiro BE. Myopathy. Electromyography and Neuromuscular Disorders 2013. [DOI: 10.1016/b978-1-4557-2672-1.00035-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
139 Katsuyuki Shinjo S, Carlos de Souza FH, Bertacini de Moraes JC. Dermatomiosite e polimiosite: da imunopatologia à imunoterapia (imunobiológicos). Revista Brasileira de Reumatologia 2013;53:105-10. [DOI: 10.1590/s0482-50042013000100010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
140 Weiss N, Eymard B. Maladies musculaires en réanimation. Quand les évoquer ? Comment orienter la recherche diagnostique ? Réanimation 2012;21:583-605. [DOI: 10.1007/s13546-012-0515-4] [Reference Citation Analysis]
141 Kubota A, Shimizu J, Iwata A, Tsuji S. Aberrant expression of myogenin in inclusion body myositis: Immunohistochemical studies of transcription factors regulating myogenesis in inflammatory myopathies. Clin Exp Neuroimmunol 2012;3:129-137. [DOI: 10.1111/cen3.12000] [Reference Citation Analysis]
142 Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis 2011;3:315-24. [PMID: 22870489 DOI: 10.1177/1759720X11415306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
143 Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;:CD003643. [PMID: 22895935 DOI: 10.1002/14651858.CD003643.pub4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 61] [Article Influence: 3.5] [Reference Citation Analysis]
144 Filková M, Hulejová H, Kuncová K, Pleštilová L, Cerezo LA, Mann H, Klein M, Zámečník J, Gay S, Vencovský J, Senolt L. Resistin in idiopathic inflammatory myopathies. Arthritis Res Ther 2012;14:R111. [PMID: 22577940 DOI: 10.1186/ar3836] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
145 Revannasiddaiah S, Gupta MK, Rastogi M, Kesari AA, Seam RK, Gupta M, Chauhan S, Madabhavi I. Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis. BMJ Case Rep 2012;2012:bcr0120125585. [PMID: 22602825 DOI: 10.1136/bcr.01.2012.5585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
146 Benveniste O. Classification, pathogénie et traitement des myosites dysimmunitaires. Pratique Neurologique - FMC 2012;3:119-127. [DOI: 10.1016/j.praneu.2012.01.014] [Reference Citation Analysis]
147 Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S, Ogura T, Mizusawa H, Imai T, Miyasaka N, Nanki T. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther 2012;14:R48. [PMID: 22394569 DOI: 10.1186/ar3761] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
148 Doma S, Wo JM, Parkman HP. Esophageal Involvement in Systemic Diseases. The Esophagus 2012. [DOI: 10.1002/9781444346220.ch18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Balcı DD, Celik E, Sarıkaya G, Yenin JZ, Atik E. The co-existence of vulvar lichen sclerosus, ulcerated calcinosis cutis, and dermatomyositis: coincidence or immunological mechanism? Ann Dermatol 2011;23:S375-9. [PMID: 22346282 DOI: 10.5021/ad.2011.23.S3.S375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
150 Dalakas MC. Inflammatory and Autoimmune Features of Inclusion‐Body Myositis. Muscle Aging, Inclusion‐Body Myositis and Myopathies 2012. [DOI: 10.1002/9781444398311.ch8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Crum BA, Rubin DI, Dimberg EL, Goodman BP. Neuromuscular Disorders. Neurology 2012. [DOI: 10.1007/978-0-387-88555-1_9] [Reference Citation Analysis]
152 Amato AA, Kissel JT. Inflammatory Myopathies. Swaiman's Pediatric Neurology 2012. [DOI: 10.1016/b978-1-4377-0435-8.00090-1] [Reference Citation Analysis]
153 Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int. 2012;32:3587-3590. [PMID: 22090006 DOI: 10.1007/s00296-011-2220-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
154 van Dooren SH, Raijmakers R, Pluk H, Lokate AM, Koemans TS, Spanjers RE, Heck AJ, Boelens WC, van Venrooij WJ, Pruijn GJ. Oxidative stress-induced modifications of histidyl-tRNA synthetase affect its tRNA aminoacylation activity but not its immunoreactivity. Biochem Cell Biol 2011;89:545-53. [PMID: 22047085 DOI: 10.1139/o11-055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
155 Ramesha KN, Kuruvilla A, Sarma PS, Radhakrishnan VV. Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases. Ann Indian Acad Neurol 2010;13:250-6. [PMID: 21264132 DOI: 10.4103/0972-2327.74190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
156 Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord 2008;1:157-66. [PMID: 21180574 DOI: 10.1177/1756285608097463] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
157 . P. Acute Medicine 2011. [DOI: 10.1017/cbo9780511835278.017] [Reference Citation Analysis]
158 Perdivara I, Peddada SD, Miller FW, Tomer KB, Deterding LJ. Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes. J Proteome Res 2011;10:2969-78. [PMID: 21609021 DOI: 10.1021/pr200397h] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
159 Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343-354. [PMID: 21654717 DOI: 10.1038/nrneurol.2011.63] [Cited by in Crossref: 128] [Cited by in F6Publishing: 137] [Article Influence: 10.7] [Reference Citation Analysis]
160 Rugiero M, Bettini M. Miositis por cuerpos de inclusión: ¿una enfermedad subdiagnosticada? Neurología Argentina 2011;3:100-105. [DOI: 10.1016/s1853-0028(11)70022-2] [Reference Citation Analysis]
161 Yoon J, Kim SH, Ki CS, Kwon MJ, Lim MJ, Kwon SR, Joo K, Moon CG, Park W. Carrier woman of Duchenne muscular dystrophy mimicking inflammatory myositis. J Korean Med Sci 2011;26:587-91. [PMID: 21468271 DOI: 10.3346/jkms.2011.26.4.587] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
162 Lundberg IE. Inflammatory muscle disease—etiology and pathogenesis (myositis). Rheumatology 2011. [DOI: 10.1016/b978-0-323-06551-1.00145-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Dalakas MC. Treatment and Management of Autoimmune Myopathies. Neuromuscular Disorders: Treatment and Management 2011. [DOI: 10.1016/b978-1-4377-0372-6.00021-9] [Reference Citation Analysis]
164 Vleugels RA, Callen JP. Dermatomyositis. Autoimmune Diseases of the Skin 2011. [DOI: 10.1007/978-3-211-99225-8_11] [Reference Citation Analysis]
165 O’rourke KS. Sarcopenia and Myopathies in the Elderly. Geriatric Rheumatology 2011. [DOI: 10.1007/978-1-4419-5792-4_27] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Limaye VS, Lester S, Bardy P, Thompson P, Cox S, Blumbergs P, Roberts-Thomson P. A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 2012;32:611-9. [PMID: 21125283 DOI: 10.1007/s00296-010-1637-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
167 Wang H, Li H, Kai C, Deng J. Polymyositis associated with hypothyroidism or hyperthyroidism: two cases and review of the literature. Clin Rheumatol 2011;30:449-58. [PMID: 20857158 DOI: 10.1007/s10067-010-1570-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
168 Grau JM, Prieto-González S. [Biologic agents in myositis: unsolved questions]. Med Clin (Barc) 2010;135:263-4. [PMID: 20451933 DOI: 10.1016/j.medcli.2010.02.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Mitsui T, Kunishige M, Kuroda Y, Kaji R. Heterogeneous Muscular Involvement in Inclusion Body Myositis. Lab Med 2010;41:393-6. [DOI: 10.1309/lm4y47nlhqvhsupx] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Dalakas MC. Dermatomyositis. International Neurology 2010. [DOI: 10.1002/9781444317008.ch122] [Reference Citation Analysis]
171 Dalakas MC. Polymyositis. International Neurology 2010. [DOI: 10.1002/9781444317008.ch123] [Reference Citation Analysis]
172 Mustafa KN, Dahbour SS. Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol 2010;29:1381-5. [PMID: 20407818 DOI: 10.1007/s10067-010-1465-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
173 Description of muscle disease – specific diseases. Disorders of Voluntary Muscle 2010. [DOI: 10.1017/cbo9780511674747.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
174 Dastmalchi M, Alexandersson H. Targeted Treatment of the Idiopathic Inflammatory Myopathies. Targeted Treatment of the Rheumatic Diseases 2010. [DOI: 10.1016/b978-1-4160-9993-2.00014-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Recher M, Sahrbacher U, Bremer J, Arndt B, Steiner U, Fontana A. Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatol Int 2012;32:469-72. [PMID: 20044785 DOI: 10.1007/s00296-009-1290-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
176 Lundberg IE, Munters LA. Inflammatory Myopathies. Muscle Pain: Diagnosis and Treatment 2010. [DOI: 10.1007/978-3-642-05468-6_8] [Reference Citation Analysis]
177 Jung HH, Bremer J, Weller M. Gene therapy for myositis. Gene Therapy for Autoimmune and Inflammatory Diseases 2010. [DOI: 10.1007/978-3-0346-0165-8_6] [Reference Citation Analysis]
178 Duró Pujol JC. Miopatías inflamatorias idiopáticas. Reumatología Clínica 2010. [DOI: 10.1016/b978-84-8086-645-3.50015-9] [Reference Citation Analysis]
179 Ballow M, Lehman HK. Intravenous Immune Serum Globulin (IVIG) Therapy in Patients with Antibody Immune Deficiency. Pediatric Allergy: Principles and Practice 2010. [DOI: 10.1016/b978-1-4377-0271-2.00017-1] [Reference Citation Analysis]
180 Jones G, Razdan D, Cracchiolo B, Houck K, Sharer L. Paraneoplastic SIADH and Dermatomyositis in Cervical Cancer: A Case Report and Literature Review. Case Rep Oncol 2009;2:203-9. [PMID: 20737038 DOI: 10.1159/000255724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
181 MRS in musculoskeletal disease. Clinical MR Spectroscopy 2009. [DOI: 10.1017/cbo9780511770647.015] [Reference Citation Analysis]
182 Jay CM, Levonyak N, Nemunaitis G, Maples PB, Nemunaitis J. Hereditary Inclusion Body Myopathy (HIBM2). Gene Regul Syst Bio 2009;3:181-90. [PMID: 20054407 DOI: 10.4137/grsb.s2594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
183 Cook IJ. Oropharyngeal dysphagia. Gastroenterol Clin North Am 2009;38:411-31. [PMID: 19699405 DOI: 10.1016/j.gtc.2009.06.003] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 7.4] [Reference Citation Analysis]
184 Bielsa Marsol I. Dermatomiositis. Reumatología Clínica 2009;5:216-222. [DOI: 10.1016/j.reuma.2008.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
185 Sánchez-Ramón S, Ravell JC, de la Torre I, Montoro M, Rodríguez-Mahou M, Carreño-Pérez L, Fernández-Cruz E, López-Longo FJ. Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy. Rheumatol Int 2010;30:817-9. [PMID: 19536548 DOI: 10.1007/s00296-009-1000-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
186 Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009;132:1536-44. [PMID: 19454532 DOI: 10.1093/brain/awp104] [Cited by in Crossref: 147] [Cited by in F6Publishing: 155] [Article Influence: 10.5] [Reference Citation Analysis]
187 Selva-o’callaghan A, Grau-junyent J, Trallero-araguás E, Labrador-horrillo M. Miopatías inflamatorias idiopáticas. Medicine - Programa de Formación Médica Continuada Acreditado 2009;10:2073-2082. [DOI: 10.1016/s0304-5412(09)71711-1] [Reference Citation Analysis]
188 Jang EJ, Kim HA, Sung JM, Lee JW, Hwang EK, Kim HC, Han JH, Suh CH. Dermatomyositis with Diffuse Large B Cell Lymphoma. J Korean Rheum Assoc 2009;16:323. [DOI: 10.4078/jkra.2009.16.4.323] [Reference Citation Analysis]
189 Polymyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_25] [Reference Citation Analysis]
190 Classic Dermatomyositis in Adults. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_19] [Reference Citation Analysis]
191 Atkinson JB, Johnson MD, Bouldin TW, Whetsell WO. Muscle and Nerve Biopsy. Modern Surgical Pathology 2009. [DOI: 10.1016/b978-1-4160-3966-2.00053-9] [Reference Citation Analysis]
192 Classification of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_3] [Reference Citation Analysis]
193 Differential Diagnosis of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_35] [Reference Citation Analysis]
194 Pathology and Immunopathology of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_33] [Reference Citation Analysis]
195 Bielsa Marsol I. Dermatomyositis. Reumatología Clínica (English Edition) 2009;5:216-222. [DOI: 10.1016/s2173-5743(09)70124-8] [Reference Citation Analysis]
196 Muscle Enzymes. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_30] [Reference Citation Analysis]
197 Bielsa I. New Antibodies in Dermatomyositis. Actas Dermo-Sifiliográficas (English Edition) 2009;100:182-189. [DOI: 10.1016/s1578-2190(09)70043-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
198 Introduction. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_1] [Reference Citation Analysis]
199 Swenson MR. Neuroimmunology. Atlas of Clinical Neurology 2009. [DOI: 10.1007/978-1-57340-359-7_13] [Reference Citation Analysis]
200 Overlap Syndromes. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_23] [Reference Citation Analysis]
201 Musculoskeletal Involvement in Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_8] [Reference Citation Analysis]
202 Cutaneous Manifestations of Dermatomayositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_6] [Reference Citation Analysis]
203 Epidemiology of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
204 Etiology of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_36] [Reference Citation Analysis]
205 Laboratory Assessments of Disease Activity in DM. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_32] [Reference Citation Analysis]
206 “Inclusion Body” Myositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_26] [Reference Citation Analysis]
207 Ophthalmic Complications of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_13] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
208 Charalabopoulos K, Charalabopoulos A, Papaioannides D. Diabetes mellitus type I associated with dermatomyositis: an extraordinary rare case with a brief literature review. BMJ Case Rep 2009;2009:bcr10. [PMID: 21686441 DOI: 10.1136/bcr.10.2008.1158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
209 Pulmonary Complications of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_11] [Reference Citation Analysis]
210 Pathophysiology, Hypotheses for Pathogenesis and Animal Models of DM. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_38] [Reference Citation Analysis]
211 Chowdhury MH, Nagai A, Terashima M, Sheikh A, Murakawa Y, Kobayashi S, Yamaguchi S. Chemokine-like factor expression in the idiopathic inflammatory myopathies. Acta Neurol Scand 2008;118:106-14. [PMID: 18294340 DOI: 10.1111/j.1600-0404.2007.00990.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
212 Rosenfeld MR, Dalmau J. Paraneoplastic Syndromes of the Nervous System. Cancer Neurology In Clinical Practice. [DOI: 10.1007/978-1-59745-412-4_15] [Reference Citation Analysis]
213 Jay C, Nemunaitis G, Nemunaitis J, Senzer N, Hinderlich S, Darvish D, Ogden J, Eager J, Tong A, Maples PB. Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2). Gene Regul Syst Bio 2008;2:243-52. [PMID: 19787087 DOI: 10.4137/grsb.s728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
214 Klein DA, Greenfield DP. Chronic benign pain. CNS Spectr 1999;4:24-31. [PMID: 18438318 DOI: 10.1017/s1092852900012141] [Reference Citation Analysis]
215 Park S, Kim S, Seong MJ, Kim S, Park J, Choi J. A Case of Lobular Panniculitis in Dermatomyositis Patient. J Korean Rheum Assoc 2008;15:54. [DOI: 10.4078/jkra.2008.15.1.54] [Reference Citation Analysis]
216 Espígol G, Grau JM. Polymyositis. Diagnostic Criteria in Autoimmune Diseases 2008. [DOI: 10.1007/978-1-60327-285-8_29] [Reference Citation Analysis]
217 Dalmau J, Rosenfeld M. Paraneoplastic Neurologic Syndromes. Abeloff's Clinical Oncology 2008. [DOI: 10.1016/b978-0-443-06694-8.50055-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
218 Oh SH, Kim SM, Sunwoo IN, Lee DH, Kim TS, Kim SH, Choi YC. The Clinical and Pathological Characteristics of Polymyositis Using ENMC Diagnostic Criteria. J Korean Rheum Assoc 2008;15:296. [DOI: 10.4078/jkra.2008.15.4.296] [Reference Citation Analysis]
219 Amato AA, Brooke MH. Disorders of Skeletal Muscle. Neurology in Clinical Practice 2008. [DOI: 10.1016/b978-0-7506-7525-3.50121-7] [Reference Citation Analysis]
220 Selva O’callaghan A, Trallero Araguás E. Inflammatory Myopathies. Dermatomyositis, Polymyositis, and Inclusion Body Myositis. Reumatología Clínica (English Edition) 2008;4:197-206. [DOI: 10.1016/s2173-5743(08)70187-4] [Reference Citation Analysis]
221 Norwood F, Rose MR. Muscle Disorders. Evidence-based Neurology: Management of Neurological Disorders 2007. [DOI: 10.1002/9780470988350.ch24] [Reference Citation Analysis]
222 Volc-platzer B. Dermatomyositis und Polymyositis. Medizinische Therapie 2007 | 2008. [DOI: 10.1007/978-3-540-48554-4_14] [Reference Citation Analysis]
223 Alexanderson H, Lundberg IE. Inflammatory muscle disease: clinical presentation and assessment of patients. Curr Rheumatol Rep 2007;9:273-9. [PMID: 17688835 DOI: 10.1007/s11926-007-0044-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
224 Sherer Y, Shepshelovich D, Shalev T, Haviv Y, Segal E, Ehrenfeld M, Levy Y, Pauzner R, Shoenfeld Y, Langevitz P. Outcome of patients having dermatomyositis admitted to the intensive care unit. Clin Rheumatol 2007;26:1851-5. [PMID: 17332975 DOI: 10.1007/s10067-007-0588-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
225 Ota S, Kasahara A, Yamada T, Tanimoto M. Dermatomyositis with massive ascites. Rheumatol Int 2007;27:877-9. [PMID: 17287935 DOI: 10.1007/s00296-007-0305-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
226 Dalakas MC. Immunobiology of Autoimmune Inflammatory Myopathies. Neurobiology of Disease 2007. [DOI: 10.1016/b978-012088592-3/50089-x] [Reference Citation Analysis]
227 Katirji B. Case 20. Electromyography in Clinical Practice 2007. [DOI: 10.1016/b978-0-323-02899-8.50029-x] [Reference Citation Analysis]
228 Mason JW, Trehan S, Renlund DG. Myocarditis. Cardiovascular Medicine 2007. [DOI: 10.1007/978-1-84628-715-2_62] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
229 Arnett FC, Willerson JT. Connective Tissue Diseases and the Heart. Cardiovascular Medicine 2007. [DOI: 10.1007/978-1-84628-715-2_112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
230 Campo A, Hausmann G, Martí R, Estrach T, Grau J, Porcel J, Herrero C. Complement Activation Products (C3a and C5b-9) as Markers of Activity of Dermatomyositis. Comparison With Tradicional Laboratory Markers. Actas Dermo-Sifiliográficas (English Edition) 2007;98:403-414. [DOI: 10.1016/s1578-2190(07)70473-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Bockman CS, Eckerson J. Inflammatory Myopathies. xPharm: The Comprehensive Pharmacology Reference 2007. [DOI: 10.1016/b978-008055232-3.63038-7] [Reference Citation Analysis]
232 Voit T. Idiopathische entzündliche Myopathien. Pädiatrie 2007. [DOI: 10.1007/978-3-540-76460-1_217] [Reference Citation Analysis]
233 Sordet C, Goetz J, Sibilia J. Intérêt diagnostique et nosologique des autoanticorps dans les myopathies inflammatoires. Revue du Rhumatisme 2006;73:1301-1310. [DOI: 10.1016/j.rhum.2006.04.009] [Reference Citation Analysis]
234 Choy E. Myositis. Medicine 2006;34:489-92. [DOI: 10.1053/j.mpmed.2006.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
235 Brunn A, Schröder R, Deckert M. The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. Acta Neuropathol 2006;112:325-32. [PMID: 16862423 DOI: 10.1007/s00401-006-0113-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
236 Yoon C, Kim H. Extended indications for anti-tumor necrosis factor-α therapy. APLAR J Rheumatol 2006;9:193-199. [DOI: 10.1111/j.1479-8077.2006.00195.x] [Reference Citation Analysis]
237 Haustein U. Amyopathic dermatomyositis (dermatomyositis sine myositis) and cutaneous dermatomyositis with mild muscle disease. Journal of the European Academy of Dermatology and Venereology 2006;4:30-34. [DOI: 10.1111/j.1468-3083.1995.tb00280.x] [Reference Citation Analysis]
238 Traufeller K, Zierz S. Entzündliche, endokrine und toxische Muskelerkrankungen. Klinische Neurologie. [DOI: 10.1007/3-540-31176-9_11] [Reference Citation Analysis]
239 Volc-platzer B. Dermatomyositis und Polymyositis. Medizinische Therapie 2005|2006. [DOI: 10.1007/3-540-27385-9_14] [Reference Citation Analysis]
240 Cherin P. Polymyosites et dermatomyosites. EMC - Appareil locomoteur 2006;1:1-10. [DOI: 10.1016/s0246-0521(03)00139-6] [Reference Citation Analysis]
241 Benatar M. Inflammatory Myopathy. Neuromuscular Disease 2006. [DOI: 10.1007/978-1-59745-106-2_19] [Reference Citation Analysis]
242 Mori T, Nara S, Chisaka H, Wada F, Hacihsuka K. A Patient with Inclusion Body Myositis suffering from Left Thalamic Hemorrhage. Jpn J Rehabil Med 2006;43:310-314. [DOI: 10.2490/jjrm1963.43.310] [Reference Citation Analysis]
243 Dalakas MC. Dermatomyositis. Handbook of Systemic Autoimmune Diseases 2006. [DOI: 10.1016/s1571-5078(05)05011-7] [Reference Citation Analysis]
244 Cleland JA, Venzke JW, Eenkhoorn L. Dermatomyositis: ontwikkeling van een diagnose. Fysiotherapeutische casuïstiek 2006. [DOI: 10.1007/978-90-313-8645-1_69] [Reference Citation Analysis]
245 Dalakas MC. Immune-Mediated Inflammatory Myopathies. Current Therapy in Neurologic Disease 2006. [DOI: 10.1016/b978-0-323-03432-6.50093-3] [Reference Citation Analysis]
246 Munshi SK, Thanvi B, Jonnalagadda SJ, Da Forno P, Patel A, Sharma S. Inclusion body myositis: an underdiagnosed myopathy of older people. Age Ageing 2006;35:91-4. [PMID: 16364943 DOI: 10.1093/ageing/afj014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
247 Stojkovic T, Dubucquoi S. [The use of intravenous immunoglobulins in neurology]. Rev Neurol (Paris) 2005;161:781-94. [PMID: 16244560 DOI: 10.1016/s0035-3787(05)85137-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
248 Bataller L, Dalmau J. PARANEOPLASTIC DISORDERS OF THE NERVOUS SYSTEM. CONTINUUM: Lifelong Learning in Neurology 2005;11:69-92. [DOI: 10.1212/01.con.0000293680.24426.ae] [Reference Citation Analysis]
249 Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005;252 Suppl 1:I14-8. [PMID: 15959667 DOI: 10.1007/s00415-005-1104-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
250 Bromberg MB. Advances in Diagnosis and Management of Inflammatory Myopathies. Journal of Clinical Neuromuscular Disease 2005;6:167-179. [DOI: 10.1097/01.cnd.0000167480.39597.95] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
251 Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201:591-601. [PMID: 15728237 DOI: 10.1084/jem.20041367] [Cited by in Crossref: 276] [Cited by in F6Publishing: 289] [Article Influence: 15.3] [Reference Citation Analysis]
252 Michels H, Burmester GR, Buttgereit F. [Intravenous immunoglobulins in chronic idiopathic myositis]. Z Rheumatol 2005;64:102-10. [PMID: 15793676 DOI: 10.1007/s00393-005-0695-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
253 Alhatou MI, Sladky JT, Bagasra O, Glass JD. Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology. J Mol Histol 2004;35:615-9. [PMID: 15614615 DOI: 10.1007/s10735-004-2194-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
254 Chevrel G, Granet C, Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005;64:1257-62. [PMID: 15731288 DOI: 10.1136/ard.2004.032359] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 2.8] [Reference Citation Analysis]
255 Bharucha AE, Camilleri M. Management of Gut Dysmotility. Peripheral Neuropathy 2005. [DOI: 10.1016/b978-0-7216-9491-7.50124-1] [Reference Citation Analysis]
256 Bielsa Marsol I. Manifestaciones cutáneas de las miopatías inflamatorias idiopáticas. Piel 2005;20:22-27. [DOI: 10.1016/s0213-9251(05)72217-6] [Reference Citation Analysis]
257 Petiot P, Urtizberea J. Diagnostic des maladies musculaires. EMC - Neurologie 2004;1:137-155. [DOI: 10.1016/j.emcn.2004.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
258 Kamali S, Cefle A, Sayarlioglu M, Gul A, Inanc M, Ocal L, Aral O, Konice M. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol Int 2005;25:211-4. [PMID: 14722731 DOI: 10.1007/s00296-003-0422-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
259 Park IW, Suh YJ, Han JH, Shin YS, Choi JH, Park HS, Suh CH. Dermatomyositis developing in the first trimester of pregnancy. Korean J Intern Med 2003;18:196-8. [PMID: 14619391 DOI: 10.3904/kjim.2003.18.3.196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
260 Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004;5:153-60. [PMID: 15186194 DOI: 10.2165/00128071-200405030-00003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
261 Sultan S, Isenberg DA. Inflammatory Muscle Diseases: Pathogenesis and Clinical Features. Handbook of Systemic Autoimmune Diseases 2004. [DOI: 10.1016/s1571-5078(04)03007-7] [Reference Citation Analysis]
262 Zampieri S, Ghirardello A, Iaccarino L, Gambari PF, Doria A. Infections and Polymyositis-Dermatomyositis. Infection and Autoimmunity 2004. [DOI: 10.1016/b978-044451271-0.50045-4] [Reference Citation Analysis]
263 Petiot P, Urtizberea JA. Diagnostic des maladies musculaires. EMC - Neurologie 2004;1:1-12. [DOI: 10.1016/s0246-0378(04)35623-x] [Reference Citation Analysis]
264 Controlled Studies with High-Dose Intravenous Immunoglobulin in the Treatment of Inclusion Body Myositis. Intravenous Immunoglobulins in the Third Millennium 2003. [DOI: 10.3109/9780203325940-43] [Reference Citation Analysis]
265 Intravenous Immunoglobulin in Polymyositis and Dermatomyositis. Intravenous Immunoglobulins in the Third Millennium 2003. [DOI: 10.3109/9780203325940-42] [Reference Citation Analysis]
266 Loutfy MR, Sheehan NL, Goodhew JE, Walmsley SL. Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity. AIDS 2003;17:1266-7. [DOI: 10.1097/00002030-200305230-00024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
267 Williams RB, Grehan MJ, Hersch M, Andre J, Cook IJ. Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia. Gut 2003;52:471-8. [PMID: 12631653 DOI: 10.1136/gut.52.4.471] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 3.3] [Reference Citation Analysis]
268 Hofbauer M, Wiesener S, Babbe H, Roers A, Wekerle H, Dornmair K, Hohlfeld R, Goebels N. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci U S A 2003;100:4090-5. [PMID: 12651958 DOI: 10.1073/pnas.0236183100] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 4.0] [Reference Citation Analysis]
269 Ascherman DP. Pulmonary complications of inflammatory myopathy. Curr Rheumatol Rep 2002;4:409-14. [PMID: 12217246 DOI: 10.1007/s11926-002-0086-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
270 Bella IR, Chad DA. Inflammatory Myopathy. Office Practice of Neurology 2003. [DOI: 10.1016/b0-44-306557-8/50110-6] [Reference Citation Analysis]
271 Schröder JO, Grimbacher B, Sticherling M, Lorenz H, Moosig F, Volc-platzer B, Hunzelmann N, Gause A, Ehlert A, Müller-ladner U, Braun N, Risler T. Immunologisch bedingte Krankheiten. Medizinische Therapie in Klinik und Praxis 2003. [DOI: 10.1007/978-3-662-12451-2_3] [Reference Citation Analysis]
272 Briemberg HR, Amato AA. Chapter 20 Inflammatory myopathies. Handbook of Clinical Neurophysiology 2003. [DOI: 10.1016/s1567-4231(09)70130-3] [Reference Citation Analysis]
273 Selim M, Chad DA, Recht LD. Neuromuscular Disease and Its Complications. Cancer Neurology in Clinical Practice 2003. [DOI: 10.1007/978-1-59259-317-0_11] [Reference Citation Analysis]
274 Gómez-puerta J, Cucho Venegas M, Cervera Segura R, Font Franco J. Inmunoglobulinas endovenosas en las enfermedades autoinmunes sistémicas. Revista Clínica Española 2003;203:548-554. [DOI: 10.1016/s0014-2565(03)71352-6] [Reference Citation Analysis]
275 Swenson MR. Neuroimmunology. Atlas of Clinical Neurology 2003. [DOI: 10.1007/978-1-4757-4552-8_13] [Reference Citation Analysis]
276 Dalakas MC. Myositis, Inflammatory. Encyclopedia of the Neurological Sciences 2003. [DOI: 10.1016/b0-12-226870-9/00847-9] [Reference Citation Analysis]
277 Voit T. Juvenile Dermatomyositis und Polymyositis. Pädiatrie 2003. [DOI: 10.1007/978-3-662-09176-0_90] [Reference Citation Analysis]
278 Dalakas MC, Pongratz D. Inflammatory Myopathies. Neurological Disorders 2003. [DOI: 10.1016/b978-012125831-3/50290-2] [Reference Citation Analysis]
279 Voit T. Idiopathische entzündliche Myopathien. Pädiatrie 2003. [DOI: 10.1007/978-3-662-09176-0_217] [Reference Citation Analysis]
280 Cherin P. Polimiositis y dermatomiositis. EMC - Aparato Locomotor 2003;36:1-11. [DOI: 10.1016/s1286-935x(03)72284-9] [Reference Citation Analysis]
281 Dalmau J, Graus F. Paraneoplastic Syndromes. Office Practice of Neurology 2003. [DOI: 10.1016/b0-44-306557-8/50180-5] [Reference Citation Analysis]
282 The role of high-dose intravenous immunoglobulin in dermatomyositis. Intravenous Immunoglobulins in Dermatology 2002. [DOI: 10.3109/9780203627051-8] [Reference Citation Analysis]
283 Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420-8. [PMID: 12235311 DOI: 10.1136/jnnp.73.4.420] [Cited by in Crossref: 223] [Cited by in F6Publishing: 237] [Article Influence: 10.6] [Reference Citation Analysis]
284 Choy E. Myositis. Medicine 2002;30:42-4. [DOI: 10.1383/medc.30.10.42.28257] [Reference Citation Analysis]
285 Sekine H, Ohya K, Kojima S, Mizuguchi K. Dermatomyositis Associated With Urachal Adenocarcinoma. The Journal of Urology 2002. [DOI: 10.1097/00005392-200210010-00046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
286 Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, Rose MR, Scolding N, Webster AD. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002;72:440-8. [PMID: 11909900 DOI: 10.1136/jnnp.72.4.440] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
287 Schoser BG, Blottner D, Stuerenburg HJ. Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol Scand 2002;105:309-13. [PMID: 11939944 DOI: 10.1034/j.1600-0404.2002.1o104.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 1.9] [Reference Citation Analysis]
288 Cherin P, Gherardi RK. Macrophagic myofasciitis. Curr Rheumatol Rep 2000;2:196-200. [PMID: 11123059 DOI: 10.1007/s11926-000-0079-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
289 Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000;2:216-24. [PMID: 11123062 DOI: 10.1007/s11926-000-0082-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 3.6] [Reference Citation Analysis]
290 Liu CC, Ahearn JM. Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective. Curr Rheumatol Rep 2001;3:325-33. [PMID: 11470052 DOI: 10.1007/s11926-001-0037-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
291 Cardellach F, Selva A, Grau JM, de Caralt TM. Mujer de 44 años con artralgias y neumopatía intersticial. Medicina Clínica 2002;119:189-196. [DOI: 10.1016/s0025-7753(02)73357-5] [Reference Citation Analysis]
292 Amato AA, Dumitru D. Acquired Myopathies. Elextrodiagnostic Medicine 2002. [DOI: 10.1016/b978-1-56053-433-4.50036-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
293 Rohkamm R. Muskelerkrankungen und neuromuskuläre Störungen. Neurologische Therapie 2002. [DOI: 10.1007/978-3-642-56398-0_22] [Reference Citation Analysis]
294 Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Seelig HP, Renz M, Mierau R, Genth E, Pruijn GJ, van Venrooij WJ. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002;4:134-8. [PMID: 11879549 DOI: 10.1186/ar389] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 2.7] [Reference Citation Analysis]
295 Gilbert DT, Morgan O, Smikle MF, Simeon D, Barton EN. HTLV-1 associated polymyositis in Jamaica. Acta Neurol Scand 2001;104:101-4. [PMID: 11493227 DOI: 10.1034/j.1600-0404.2001.104002101.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 1.5] [Reference Citation Analysis]
296 Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001;124:282-9. [PMID: 11422206 DOI: 10.1046/j.1365-2249.2001.01499.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
297 Rouger K, Louboutin JP, Villanova M, Cherel Y, Fardeau M. X-linked vacuolated myopathy : TNF-alpha and IFN-gamma expression in muscle fibers with MHC class I on sarcolemma. Am J Pathol 2001;158:355-9. [PMID: 11159171 DOI: 10.1016/s0002-9440(10)63976-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
298 Nóbrega ODT, Karnikowski MGDO. Polymyositis. Rev Neurocienc 2001;18:186-188. [DOI: 10.34024/rnc.2010.v18.8498] [Reference Citation Analysis]
299 Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grøndal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23. [PMID: 11156543 DOI: 10.1136/ard.60.2.116] [Cited by in Crossref: 267] [Cited by in F6Publishing: 287] [Article Influence: 12.1] [Reference Citation Analysis]
300 Francès C, Piette J. Vascular Manifestations in Rheumatoid Arthritis, Dermato/Polymyositis, and Mixed Connective Tissue Disease. Vascular Manifestations of Systemic Autoimmune Diseases 2001. [DOI: 10.1201/9781420040395.ch23] [Reference Citation Analysis]
301 Lindner A, Zierz S. Polymyositis, Dermatomyositis, Einschlusskörpermyositis und okuläre Myositis. Immunglobuline in der klinischen Neurologie 2001. [DOI: 10.1007/978-3-642-93716-3_4] [Reference Citation Analysis]
302 Lenard HG, Voit T, Hübner C, von Moers A. Krankheiten der Muskulatur. Pädiatrie 2001. [DOI: 10.1007/978-3-662-12660-8_23] [Reference Citation Analysis]
303 Woolliscroft JO. M. Current Diagnosis & Treatment 2001. [DOI: 10.1007/978-1-4684-0614-6_13] [Reference Citation Analysis]
304 Roger P, Fouché R, Tiger F, Vandenbos F, Bernardin G, Fuzibet J, Perrin C, Michiels J, Dellamonica P, Mattéi M. Myosites inflammatoires en réanimation Á propos de trois cas. Réanimation Urgences 2000;9:580-584. [DOI: 10.1016/s1164-6756(00)90067-7] [Reference Citation Analysis]
305 Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000;68:472-8. [PMID: 10727483 DOI: 10.1136/jnnp.68.4.472] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 5.5] [Reference Citation Analysis]
306 Mateos González M, López-laso E, Gómez Reino J, Simón de las Heras R, Mateos Beato F. Dermatomiositis en la infancia. Anales de Pediatría 2000;52:424-9. [DOI: 10.1016/s1695-4033(00)77374-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
307 Fieschi C, Piette J. Myositis and Neoplasia. Cancer and Autoimmunity 2000. [DOI: 10.1016/b978-044450331-2/50010-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
308 Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155:453-60. [PMID: 10433938 DOI: 10.1016/s0002-9440(10)65141-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 3.7] [Reference Citation Analysis]
309 Mastaglia FL, Phillips BA, Zilko PJ. Inflammatory Myopathy. Curr Treat Options Neurol 1999;1:263-72. [PMID: 11096714 DOI: 10.1007/s11940-999-0008-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
310 Cook IJ, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. Gastroenterology 1999;116:455-78. [PMID: 9922328 DOI: 10.1016/s0016-5085(99)70144-7] [Cited by in Crossref: 347] [Cited by in F6Publishing: 355] [Article Influence: 14.5] [Reference Citation Analysis]
311 Hertel K, Stephan M, Zierz S. Entzündliche, endokrine und toxische Muskelerkrankungen. Klinische Neurologie 1999. [DOI: 10.1007/978-3-662-08118-1_11] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
312 Lynch JP, Orens JB, Kazerooni E. Collagen Vascular Diseases. Diffuse Lung Disorders 1999. [DOI: 10.1007/978-1-4471-3440-4_16] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
313 Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human Muscle Cells Express a Functional Costimulatory Molecule Distinct from B7.1 (CD80) and B7.2 (CD86) In Vitro and in Inflammatory Lesions. The Journal of Immunology 1998;161:5943-5951. [DOI: 10.4049/jimmunol.161.11.5943] [Reference Citation Analysis]
314 Basta M, Dalakas M. Complement and Neuromuscular Diseases. The Human Complement System in Health and Disease 1998. [DOI: 10.1201/b14212-29] [Reference Citation Analysis]
315 Brannagan TH, Hays AP, Lange DJ, Trojaborg W. The role of quantitative electromyography in inclusion body myositis. J Neurol Neurosurg Psychiatry 1997;63:776-9. [PMID: 9416815 DOI: 10.1136/jnnp.63.6.776] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 0.8] [Reference Citation Analysis]
316 K�ller H, Stoll G. Azathioprine hypersensitivity reactions: Caution upon rechallenge (a reply). Muscle Nerve 1997;20:1467-1468. [DOI: 10.1002/(sici)1097-4598(199711)20:11<1467::aid-mus20>3.0.co;2-y] [Reference Citation Analysis]
317 Gold R, Hartung HP, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 1997;20:399-404. [PMID: 9292968 DOI: 10.1016/s0166-2236(97)01079-5] [Cited by in Crossref: 122] [Cited by in F6Publishing: 125] [Article Influence: 4.7] [Reference Citation Analysis]
318 Hausmanowa-petrusewicz I, Kowalska-oledzka E, Miller FW, Jarzabek-chorzelska M, Targoff IN, Blaszczyk-kostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. Arthritis & Rheumatism 1997;40:1257-1266. [DOI: 10.1002/art.1780400710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
319 Kulkarni A, Ravi TJ, Brodmerkel GJ Jr, Agrawal RM. Inflammatory myositis in association with inflammatory bowel disease. Dig Dis Sci 1997;42:1142-5. [PMID: 9201074 DOI: 10.1023/a:1018825301263] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
320 Busse O, Jörg J, Rumpl E, Krauseneck P, Besser R, Schwalen S, Prange HW, Hartung H, Hennen G, Rohkamm R, Grotemeyer K, Rieß O. Therapie der einzelnen Krankheitsbilder. Neurologische Therapie 1997. [DOI: 10.1007/978-3-642-97934-7_3] [Reference Citation Analysis]
321 Feist E, Dörner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzel PM. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996;184:1313-8. [PMID: 8879203 DOI: 10.1084/jem.184.4.1313] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 2.2] [Reference Citation Analysis]
322 Behan WM, Gow JW, Simpson K, Behan PO. Search for picornaviruses at onset of inflammatory myopathy. J Clin Pathol 1996;49:592-4. [PMID: 8813962 DOI: 10.1136/jcp.49.7.592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
323 Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905-10. [PMID: 8675705 DOI: 10.1172/JCI118749] [Cited by in Crossref: 194] [Cited by in F6Publishing: 201] [Article Influence: 7.2] [Reference Citation Analysis]
324 Otten A, Vermeulen M, Bossuyt PM, Otten A. Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 1996;60:359-61. [PMID: 8774395 DOI: 10.1136/jnnp.60.4.359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
325 Jardin H, Cailleux N, Marie I, Lévesque H, Courtois H. [Association of polymyositis and rheumatoid arthritis. Apropos of a new case not related to drug ingestion]. Rev Med Interne 1996;17:321-4. [PMID: 8761796 DOI: 10.1016/0248-8663(96)81436-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
326 Sperling R, Sperling J. 56-kd Nuclear Protein Autoantibodies. Autoantibodies 1996. [DOI: 10.1016/b978-044482383-0/50039-x] [Reference Citation Analysis]
327 Narayana PA, Jackson EF, Butler IJ. 1H-MRS of Muscle Physiology and Pathophysiology. Muscle Imaging in Health and Disease 1996. [DOI: 10.1007/978-1-4612-2314-6_8] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
328 Garlepp MJ, Chen W, Tabarias H, Baines M, Brooks A, McCluskey J. Antigen processing and presentation by a murine myoblast cell line. Clin Exp Immunol 1995;102:614-9. [PMID: 8536381 DOI: 10.1111/j.1365-2249.1995.tb03861.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.0] [Reference Citation Analysis]
329 Dalakas MC. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 1995;15:70S-5S. [PMID: 8613495 DOI: 10.1007/BF01540896] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
330 Smadja D, Bellance R, Cabre P, Arfi S, Vernant JC. Clinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique. Acta Neurol Scand 1995;92:206-12. [PMID: 7484073 DOI: 10.1111/j.1600-0404.1995.tb01689.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
331 Hilton-jones D. Myopathies. Rev Clin Gerontol 1995;5:275-288. [DOI: 10.1017/s0959259800004329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
332 O'Hanlon TP, Messersmith WA, Dalakas MC, Plotz PH, Miller FW. Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. Clin Exp Immunol 1995;100:519-28. [PMID: 7774065 DOI: 10.1111/j.1365-2249.1995.tb03732.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
333 Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med 1995;181:1863-8. [PMID: 7722460 DOI: 10.1084/jem.181.5.1863] [Cited by in Crossref: 108] [Cited by in F6Publishing: 112] [Article Influence: 3.9] [Reference Citation Analysis]
334 Considine DM, Considine GD. D. Van Nostrand’s Scientific Encyclopedia 1995. [DOI: 10.1007/978-1-4757-6918-0_4] [Reference Citation Analysis]
335 Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-35. [PMID: 7962520 DOI: 10.1172/JCI117520] [Cited by in Crossref: 273] [Cited by in F6Publishing: 275] [Article Influence: 9.4] [Reference Citation Analysis]
336 Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994;98:40-5. [PMID: 7923882 DOI: 10.1111/j.1365-2249.1994.tb06604.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 2.2] [Reference Citation Analysis]
337 Lindberg C, Persson LI, Björkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-31. [PMID: 8191875 DOI: 10.1111/j.1600-0404.1994.tb01647.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 84] [Article Influence: 2.7] [Reference Citation Analysis]
338 Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, Tonali P. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994;95:166-72. [PMID: 7507012 DOI: 10.1111/j.1365-2249.1994.tb06032.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 85] [Article Influence: 2.7] [Reference Citation Analysis]
339 Mortier W. Muskelerkrankungen. Therapie der Krankheiten des Kindesalters 1994. [DOI: 10.1007/978-3-662-22535-6_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
340 Hohlfeld R, Engel AG. Autoimmune diseases of muscle. Immunology of Neuromuscular Disease 1994. [DOI: 10.1007/978-94-011-1422-6_9] [Reference Citation Analysis]
341 Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res 1993;12:244-57. [PMID: 8288945 DOI: 10.1007/BF02918256] [Cited by in Crossref: 110] [Cited by in F6Publishing: 118] [Article Influence: 3.7] [Reference Citation Analysis]
342 Jongen PJ, Zoll GJ, Beaumont M, Melchers WJ, van de Putte LB, Galama JM. Polymyositis and dermatomyositis: no persistence of enterovirus or encephalomyocarditis virus RNA in muscle. Ann Rheum Dis 1993;52:575-8. [PMID: 8215618 DOI: 10.1136/ard.52.8.575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
343 Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, Mora M, Cornelio F, Steinman L. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. J Clin Invest 1993;91:2880-6. [PMID: 8514895 DOI: 10.1172/JCI116533] [Cited by in Crossref: 119] [Cited by in F6Publishing: 122] [Article Influence: 4.0] [Reference Citation Analysis]
344 Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993;71:351-61. [PMID: 8389626 DOI: 10.1007/BF00186623] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 0.8] [Reference Citation Analysis]
345 Bilak M, Askanas V, Engel WK. Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. Acta Neuropathol 1993;85:378-82. [PMID: 8386897 DOI: 10.1007/BF00334447] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.0] [Reference Citation Analysis]
346 Angelini C, Menegazzo E, Fanin M. Multifactorial study of inflammatory myopathies. Report of 29 cases. Ital J Neurol Sci 1993;14:69-76. [PMID: 8473155 DOI: 10.1007/BF02339045] [Reference Citation Analysis]
347 Del Bigio MR, Jay V. Inclusion body myositis with abundant ring fibers. Acta Neuropathol 1992;85:105-10. [PMID: 1337419 DOI: 10.1007/BF00304640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
348 Polymyositis. N Engl J Med 1992;326:1293-1293. [DOI: 10.1056/nejm199205073261915] [Reference Citation Analysis]